Skip to NavigationSkip to content

Roche's Kadcyla beats Herceptin breast cancer disease recurrence and death risk

Published on 16/10/18 at 11:24am

Roche has unveiled new data for its antibody-drug conjugate Kadcyla (trastuzumab emtansine) in the treatment of patients with HER2-positive early breast cancer (eBC) who have residual disease (pathological invasive residual disease in the breast and/or axillary nodes) present following pre-surgery treatment.

The results from the Phase 3 KATHERINE study indicated that Kadcyla met its primary endpoint, “significantly reducing” the risk of disease recurrence or death compared to Herceptin (trastuzumab) when used as an adjuvant therapy.

“We are highly encouraged by these positive results with adjuvant Kadcyla treatment in people with HER2-positive early breast cancer who have residual disease after neoadjuvant therapy,” remarked Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “We look forward to discussions with regulatory authorities with the goal of bringing this new treatment option to patients as soon as possible.”

Full results from the study are due to be presented at the 2018 San Antonio Breast Cancer Symposium in December, and will be presented to global health authorities in the pursuit of marketing authorisation.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches